HilleVax Inc., the biotech that pulled off Boston's largest IPO of 2022, is delaying its norovirus vaccine by several months. CEO Rob Hershbeg cited logistical issues as reason for the delay.
HilleVax Inc., the biotech that pulled off Boston's largest IPO of 2022, is delaying its norovirus vaccine by several months. CEO Rob Hershbeg cited logistical issues as reason for the delay.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.